We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ferrex | LSE:FRX | London | Ordinary Share | GB00B649J414 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.45 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
DOW JONES NEWSWIRES
Forest Laboratories Inc. (FRX) and Laboratorios Almirall SA (ALM.MC) announced the U.S. Food and Drug Administration will require additional studies of the Spanish company's chronic obstructive pulmonary disease treatment.
As a result the companies don't know when they will file a new-drug application for the product. One had been anticipated late this year or early 2010.
COPD is a progressive, smoking-related lung disorder that is often fatal. Forest Labs and Almirall in 2006 reached a deal to jointly develop, market and distribute Almirall's treatment in the U.S.
Forest Labs disclosed study results in 2007 that showed single doses of inhaled aclidinium bromide produced a significant bronchodilatory response in 17 patients with COPD.
The companies said Friday the additional studies will include higher and/or more frequent dosing than previously tested.
Almirall shares were recently down 5.3% to EUR6.03 in Madrid. Forest Labs closed Thursday at $19.25 and was inactive premarket.
-By Kevin Kingsbury, Dow Jones Newswires; 201-938-2136; kevin.kingsbury@dowjones.com
1 Year Ferrex Chart |
1 Month Ferrex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions